A number of research firms have changed their ratings and price targets for BeiGene (NASDAQ: BGNE):

  • 11/14/2017 – BeiGene had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $83.00 price target on the stock, up previously from $58.00.
  • 11/14/2017 – BeiGene had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials.””
  • 11/14/2017 – BeiGene was given a new $120.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 11/13/2017 – BeiGene was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
  • 10/6/2017 – BeiGene had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $95.00 price target on the stock, up previously from $87.00.
  • 10/3/2017 – BeiGene was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $115.00 price target on the stock. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “
  • 9/28/2017 – BeiGene had its “buy” rating reaffirmed by analysts at Maxim Group. They now have a $120.00 price target on the stock, up previously from $77.00.

BeiGene, Ltd. (NASDAQ BGNE) traded up $0.17 during mid-day trading on Wednesday, hitting $85.04. The company had a trading volume of 221,600 shares, compared to its average volume of 191,976. The company has a current ratio of 9.33, a quick ratio of 9.27 and a debt-to-equity ratio of 0.20. BeiGene, Ltd. has a 1-year low of $26.43 and a 1-year high of $118.95.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to analyst estimates of $1.55 million. During the same period in the prior year, the company earned ($1.08) earnings per share. equities analysts forecast that BeiGene, Ltd. will post -3.09 EPS for the current year.

In related news, CMO Jane Huang sold 1,600 shares of BeiGene stock in a transaction on Monday, November 20th. The stock was sold at an average price of $86.25, for a total transaction of $138,000.00. Following the sale, the chief marketing officer now directly owns 264,900 shares in the company, valued at $22,847,625. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Oyler sold 150,957 shares of BeiGene stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total value of $12,152,038.50. Following the sale, the chief executive officer now owns 491,891 shares in the company, valued at $39,597,225.50. The disclosure for this sale can be found here. Insiders have sold 181,812 shares of company stock valued at $14,720,763 over the last 90 days. 19.90% of the stock is owned by corporate insiders.

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Receive News & Ratings for BeiGene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.